Evidence map›Paper›PMID 40880368›Full record

ArticlePLOS global public health2025

High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity.

Christine Prosperi, Shaun Truelove, Andrea C Carcelen, Gershom Chongwe, Francis D Mwansa, Phillimon Ndubani, Edgar Simulundu, Innocent C Bwalya, Mutinta Hamahuwa, Kelvin Kapungu and 17 more

Abstract read
In one paragraph

Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Christine ProsperiDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-1942-5319
Shaun TrueloveDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-0538-0607
Andrea C CarcelenDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.
Gershom ChongweTropical Diseases Research Center, Ndola, Zambia.ORCID https://orcid.org/0000-0003-3303-308X
Francis D MwansaGovernment of the Republic of Zambia, Ministry of Health, Lusaka, Zambia.
Phillimon NdubaniMacha Research Trust, Choma, Zambia.
Edgar SimulunduMacha Research Trust, Choma, Zambia.ORCID https://orcid.org/0000-0001-9423-0816
Innocent C BwalyaTropical Diseases Research Center, Ndola, Zambia.
Mutinta HamahuwaMacha Research Trust, Choma, Zambia.ORCID https://orcid.org/0009-0006-6301-5148
Kelvin KapunguTropical Diseases Research Center, Ndola, Zambia.
Kalumbu H MatakalaMacha Research Trust, Choma, Zambia.ORCID https://orcid.org/0000-0003-3536-2645
Gloria MusukwaMacha Research Trust, Choma, Zambia.ORCID https://orcid.org/0000-0001-7301-3521
Irene MutaleTropical Diseases Research Center, Ndola, Zambia.
Evans BethaTropical Diseases Research Center, Ndola, Zambia.
Nchimunya ChaavwaMacha Research Trust, Choma, Zambia.
Lombe KampambaTropical Diseases Research Center, Ndola, Zambia.ORCID https://orcid.org/0009-0006-3058-9946
Japhet MatobaMacha Research Trust, Choma, Zambia.
Passwell MunachoongaMacha Research Trust, Choma, Zambia.
Webster MufwambiTropical Diseases Research Center, Ndola, Zambia.
Ken SitutuTropical Diseases Research Center, Ndola, Zambia.ORCID https://orcid.org/0009-0008-0840-0451
Philip E ThumaMacha Research Trust, Choma, Zambia.ORCID https://orcid.org/0000-0002-1508-4409
Constance SakalaGovernment of the Republic of Zambia, Ministry of Health, Lusaka, Zambia.
Princess KayeyeGovernment of the Republic of Zambia, Ministry of Health, Lusaka, Zambia.
Amy K WinterDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0003-2737-7003
Matthew J FerrariCenter for Infectious Disease Dynamics, Pennsylvania State University, State College, Pennsylvania, United States of America.
William J MossDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0001-6579-3513
Simon MutemboDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America.ORCID https://orcid.org/0000-0002-5389-5966

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-campaign coverage surveys estimate the proportion of previously unvaccinated children vaccinated during supplementary immunization activities (SIA) but cannot address whether susceptible children seronegative to measles and rubella viruses were vaccinated during the SIA. We conducted a cross-sectional serosurvey nested within the November 2020 measles-rubella SIA in Zambia, systematically sampling children aged 9 months to 5 years at 30 SIA sites in Choma and Ndola Districts. A questionnaire administered to caregivers collected the child's demographic information and vaccination history. Dried blood spot specimens were collected from child participants and for Immunoglobulin-G antibodies to measles and rubella viruses by enzyme immunoassay. We used the expected vaccination probability by age derived from Demographic and Health Surveys to quantify the value of the immunization campaign, estimating the proportion of children who would not have otherwise received routine MR doses. Among children enrolled with MR vaccination data (N = 2,364), 2,214 (94%) reported at least one routine MR dose before the SIA. We estimate 5.0% [95%CI, 4.2-5.9%] (n = 118/2364) of children would not have otherwise received routine MR dose 1 without the SIA and 23.4% [95%CI, 21.7-25.1] (n = 553/2364) would not have otherwise received routine MR dose 2. Thus, 1 in 3.5 doses were given to an MR un- or under-vaccinated child who may not have received that dose in the absence of an SIA. Eighty-six percent and 90% of children were measles and rubella seropositive before vaccination during the SIA. Thirty-six percent of children with no prior routine MR dose were measles seropositive, while nine percent of children with two prior routine MR doses were measles seronegative. Although children vaccinated during this SIA were highly likely to have previously received routine vaccinations, the SIA reached a considerable number of susceptible children. Monitoring SIA effectiveness and efficiency through standardized metrics and formats is critical for impactful vaccine delivery strategies.

Identifiers

PMID40880368
PMCPMC12396667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.